Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Wegovy, works by slowing stomach emptying and reducing hunger signals in the brain—a mechanism that typically requires dose escalation over 16 to 20 weeks for optimal results. Understanding how dosing progresses helps you prepare for your weight loss journey and manage expectations around timeline and effects. PlexusDx provides personalized semaglutide protocols from licensed 503A compounding pharmacies, allowing you to find your effective dose without worrying about escalating costs.

How Semaglutide Titration Works

Semaglutide therapy begins at a low dose and increases incrementally every 4 weeks to allow your body to adapt and minimize gastrointestinal side effects. The standard initiation dose is 0.25 mg once weekly, which serves as a tolerance-building phase rather than a therapeutic dose. Most patients experience minimal appetite suppression at this stage, but their bodies begin adjusting to the medication's mechanism of action.

The dose then progresses to 0.5 mg in week 5, followed by 1.0 mg in week 9, 1.7 mg in week 13, and finally 2.4 mg in week 17—the maintenance dose used in major clinical trials. Each increment allows your gastrointestinal system to acclimate, reducing nausea and other adjustment-related side effects that commonly occur with rapid dose escalation. Some patients achieve their target weight loss at intermediate doses and remain stable without advancing to the maximum level.

Starting Dose vs. Maintenance Dose in Clinical Trials

The 2.4 mg weekly dose became the benchmark standard after the STEP trial series demonstrated the strongest weight loss outcomes at this level, with participants achieving an average 15% body weight reduction over 68 weeks. However, this maintenance dose is not appropriate for initial treatment—starting directly at 2.4 mg causes severe nausea, vomiting, and diarrhea in the majority of patients, leading to treatment discontinuation. The step-wise dosing protocol exists specifically to build tolerance while allowing your GLP-1 receptors to respond optimally.

Interestingly, not all patients require or benefit from reaching 2.4 mg; some individuals see meaningful weight loss plateau at 1.7 mg or even 1.0 mg, suggesting individual variability in therapeutic response. Genetic factors affecting GLP-1 receptor function and peptide sensitivity influence whether you reach target dose quickly or require more gradual progression. PlexusDx's Precision Peptide Genetic Test examines variants like GLP1R rs6923761, which can predict your individual response pattern to semaglutide therapy.

Dose Adjustment Beyond the Standard Protocol

Some patients experience persistent side effects even with the standard 4-week titration intervals and benefit from extended intervals between dose increases—moving to 5 or 6 weeks between increments to allow fuller adaptation. Others may pause at an intermediate dose for 2 to 4 weeks before advancing, a strategy that reduces dropout rates due to tolerability issues. Your prescribing provider can customize the titration timeline based on your reported side effects and weight loss progress without affecting your monthly cost.

Dose reductions occasionally become necessary if a patient develops intolerable side effects at a higher level; stepping back to a previous dose can restore tolerability while maintaining therapeutic benefit. Some individuals remain on doses below 2.4 mg as their long-term maintenance due to effective weight loss results or personal preference. PlexusDx compounded semaglutide injections are dosed individually based on clinical judgment, ensuring your therapy matches your body's unique tolerance and efficacy profile.

Why Your Price Stays Flat Regardless of Dose

PlexusDx charges a flat monthly rate of $149 for compounded semaglutide injections, meaning whether you're taking 0.25 mg or 2.4 mg, your cost remains constant—eliminating the financial anxiety that accompanies dose escalation with other providers. This pricing philosophy reflects the reality that dose titration is a clinical necessity, not a premium service: your dose may need to go up, but your price won't. Traditional telehealth models that charge per-dose or per-milligram create perverse incentives to underdose patients to minimize their cost burden.

Your monthly investment covers the medication itself, provider oversight, and access to PlexusDx's personalized support system, all delivered through licensed 503A compounding pharmacies serving all 50 states without requiring insurance or membership fees. HSA and FSA accounts can be used toward your semaglutide therapy, providing additional cost flexibility. Starting at $149/mo removes financial barriers to beginning treatment at the safest, lowest dose and progressing to your optimal therapeutic level.

Personalizing Your Semaglutide Dose With Genetic Insight

Individual genetic differences significantly influence how quickly your body responds to semaglutide and whether you achieve target weight loss at standard doses or require careful titration management. The FTO rs9939609 variant, which affects hunger-regulating neural pathways, and the GIPR rs1800437 variant, which influences glucose-dependent insulin secretion, both predict your medication response profile. PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptides linked to weight regulation, offering concrete insights into your biological predisposition for semaglutide effectiveness.

Knowing your genetic peptide profile allows your PlexusDx provider to anticipate your likely response pattern and adjust your titration schedule proactively—accelerating progress for rapid responders or extending intervals for those needing slower adaptation. This precision approach reduces trial-and-error dosing and improves long-term adherence by matching the medication protocol to your biology. The genetic test costs $99 as an add-on after your first month of treatment, providing personalized data that informs your dose optimization for the duration of your therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What dose of semaglutide should I start with?

You begin at 0.25 mg once weekly, regardless of your ultimate target dose. This starting dose is not therapeutic but tolerance-building, allowing your body to acclimate to GLP-1 receptor activation. PlexusDx providers follow evidence-based titration protocols to safely advance your dose every 4 weeks based on your tolerability and weight loss response.

How long does it take to reach the 2.4 mg maintenance dose?

The standard protocol advances your dose every 4 weeks over approximately 16 to 20 weeks, reaching 2.4 mg by week 17. However, your individual timeline may differ based on side effect tolerance and clinical judgment. Some patients reach therapeutic benefit at lower doses and remain stable without advancing to 2.4 mg.

Does my PlexusDx semaglutide cost increase when my dose goes up?

No. PlexusDx charges a flat $149 monthly rate for compounded semaglutide injections regardless of whether you're at 0.25 mg or 2.4 mg. Your dose may need to go up, but your price won't—eliminating financial barriers to optimal dosing.

What if I experience severe side effects during dose escalation?

Your PlexusDx provider can extend intervals between dose increases, pause at your current dose longer, or reduce to a previous dose while maintaining therapeutic benefit. Dose adjustments are based on your individual tolerability profile and don't affect your monthly cost. Most side effects improve within days to weeks as your body adapts.

Can the Precision Peptide Genetic Test predict how quickly I'll respond to semaglutide?

Yes. PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, FTO, GIPR, and MC4R genes that influence your GLP-1 receptor sensitivity and metabolic response. This $99 add-on test, available after your first month, provides personalized insights your provider uses to optimize your dose titration schedule and predict your likely therapeutic outcome.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves